W
Wedbush Latest Price Targets & Analyst Ratings
| Stock | Analyst | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|---|
551
Meta Platforms (Facebook)
META
$1.89T
|
MP
Michael Pachter
| $751.15 | $250 |
67%
downside
| Outperform | 5 years ago |
|
552
Biohaven
BHVN
$1.73B
| $16.35 | $78 |
377%
upside
| Outperform | 5 years ago |
|
|
553
Corvus Pharmaceuticals
CRVS
$434M
| $5.82 | $8 |
37%
upside
| Outperform | 5 years ago |
|
|
554
Zumiez
ZUMZ
$374M
|
JR
Jen Redding
| $21.04 | $23 |
9%
upside
| Neutral | 5 years ago |
|
555
Abercrombie & Fitch
ANF
$4.48B
|
JR
Jen Redding
| $95.22 | $16 |
83%
downside
| Outperform | 5 years ago |
|
556
Burlington
BURL
$18.6B
|
JR
Jen Redding
| $294.82 | $246 |
17%
downside
| Outperform | 5 years ago |
|
557
BioMarin Pharmaceuticals
BMRN
$11B
|
LM
Liana Moussatos
| $57.20 | $164 |
187%
upside
| Outperform | 5 years ago |
|
558
Prosperity Bancshares
PB
$6.45B
|
PW
Peter Winter
| $67.92 | $74 |
9%
upside
| Outperform | 5 years ago |
|
559
Norwegian Cruise Line
NCLH
$11.6B
|
JH
James Hardiman
| $25.62 | $60 |
134%
upside
| Outperform | 5 years ago |
|
560
Salesforce
CRM
$236B
|
SK
Steven Koenig
| $247.46 | $217 |
12%
downside
| Outperform | 5 years ago |
|
561
Caleres
CAL
$514M
|
CS
Christopher Svezia
| $15.20 | $20 |
32%
upside
| Outperform | 5 years ago |
|
562
Ultragenyx Pharmaceutical
RARE
$3.04B
|
DN
David Nierengarten
| $31.57 | $75 |
138%
upside
| Outperform | 5 years ago |
|
563
Aquestive Therapeutics
AQST
$636M
|
LM
Liana Moussatos
| $5.26 | $36 |
584%
upside
| Outperform | 5 years ago |
|
564
Gladstone Investment Corp
GAIN
$545M
|
HC
Henry Coffey
| $14.26 | $14 |
2%
downside
| Neutral | 5 years ago |
|
565
VF Corp
VFC
$5.86B
|
CS
Christopher Svezia
| $15 | $90 |
500%
upside
| Neutral | 5 years ago |
|
566
PTC
PTC
$25.4B
|
SK
Steven Koenig
| $212.45 | $86 |
60%
downside
| Neutral | 5 years ago |
|
567
US Bancorp
USB
$75.6B
| $48.55 | $55 |
13%
upside
| Neutral | 5 years ago |
|